Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Following dosing, the ARA 290 group increased their walk distance by a mean of 3.5% of baseline ( p = 0.09), whereas the placebo group increased walk distance by 1.1 % of baseline ( p = ns [not significant])
A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]
AOD-9604s key advantage is extensive human safety data from clinical trials involving nearly 900 participants, establishing excellent tolerability
Storage & Handling Store in a cool, dry, stable environment Protect from light, heat, and moisture Avoid repeated freezethaw cycles Reconstitute only in a laboratory setting using sterile bacteriostatic water or approved solvents Handle with appropriate laboratory PPE and safety procedures Refer to the Certificate of Analysis for full handling guidance
